Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Warrant (NQ:BIAFW)

0.4625 +0.0825 (+21.71%)
Streaming Delayed Price Updated: 10:33 AM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bioAffinity Technologies, Inc. - Warrant

< Previous 1 2 3 4 Next >
News headline image
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies News Update
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies News Update
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies In The News
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies In the News
From bioAffinity Technologies
Via Business Wire
News headline image
bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
AMA Issues CPT Code for bioAffinity Technologies’ CyPath® Lung Test for Early-Stage Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Presents Research Findings at UMass RNA Therapeutics Symposium
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Presents Research Findings at CYTO 2023
From bioAffinity Technologies, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.